Coverage
Filings
Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.
| 18 May 2016 |
| Ofatumumab in Combination with Fludarabine and Cyclophosphamide for Relapsed CLL accepted for priority review by FDA | 17 May 2016 |
| Genmab Announces Financial Results for the First Quarter of 2016 | 10 May 2016 |
| Articles of Association for Genmab A/S | 2 May 2016 |
| Genmab Updates Financial Guidance for 2016 | 20 Apr 2016 |